The National Institute for Health and Care Excellence (NICE) is backing NHS use of Janssen’s Darzalex via the Cancer Drugs Fund (CDF) for some adults with previously treated multiple myeloma.
The National Institute for Health and Care Excellence (NICE) is backing NHS use of Janssen’s Darzalex via the Cancer Drugs Fund (CDF) for some adults with previously treated multiple myeloma.
A combination of MSD’s Keytruda and chemotherapy extended overall survival when used as a first-line treatment of patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).
Cancer Research UK’s Commercial Partnerships Team and The Institute of Cancer Research, London, have entered into a multi-project collaboration and licensing deal with Germany’s Merck to discover and develop new anticancer therapies.
Novartis has released trial data showing that Cosentyx was “significantly more effective” than Johnson & Johnson’s rival biologic Stelara in achieving clear skin in patients with psoriasis.
The rising tide of accident and emergency attendances is being driven by long-term health conditions rather than a lack of GP provision, concludes a study by Queen Mary University of London.
UK companies Avacta and Glythera have sealed a licensing deal to develop drug conjugates using their combined technologies.
The Scottish Medicines Consortium has rejected NHS funding for four new therapies, including Bristol-Myers Squibb and Roche’s respective cancer medicines Opdivo and Gazyvaro.
US regulators have approved a supplemental New Drug Application for Boehringer Ingelheim’s lung cancer drug Gilotrif for first-line treatment of patients with metastatic non-small cell lung cancer whose tumours have non-resistant epidermal growth factor receptor.
Health officials are urging the public make sure they are up to date with MMR vaccinations after outbreaks of measles were confirmed in five areas of England.
A UK startup spun out from Oxford University in 2016 currently working on a universal flu vaccine is being backed by Google parent company Alphabet.
Shire’s Adynovi has been approved for use in Europe for on-demand and prophylactic use in patients 12 years and older with the rare bleeding disorder haemophilia A.
US regulators have further expanded the scope of AstraZeneca and MSD’s Lynparza to include treatment of patients with BCRA-mutant metastatic breast cancer.
UK supermarket giant Tesco will share anonymised sales information with partner charities in a bid to help develop insight on health policy and public health programmes.
The NHS has now chosen 138 clinical entrepreneurs to design and deliver new technological solutions and innovations in healthcare, including the appointment of five healthcare scientists working on addressing conditions such as sickle cell disease and allergic reactions.
Emergency care is now in a state of emergency as missed targets reach an all-time high, bed occupancy rates surge, and flu cases increase sharply, and health chiefs warn that patients are “dying in corridors” and the system is “on its knees”.